title: [PPARs and heart diseases].
abstract: After it has been reported that activation of PPARalpha or PPARgamma suppresses production of proinflammatory cytokines, medical interest in PPARs have grown and a huge research effort has been concentrated. Synthetic antidiabetic thiazolidinediones (TZDs) and natural prostaglandin D2 (PGD2) metabolite, 15d-PGJ2, are well known as ligands for PPARgamma. Hyperlipidemic drugs (fibrates) are synthetic PPARalpha ligands. Recent studies suggest that ligands of PPAR not only regulate glucose and lipid metabolism but also have pleiotropic effects on many tissues and cell types. Ligands of PPARs may become therapeutic agents useful in the prevention of cardiovascular diseases beyond their effects on glucose and lipid metabolism. This review will focus on the latest developments in the PPARs field and the roles of PPAR-dependent pathway in cardiovascular diseases.
authors.affiliation: Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Takano
authors.forename: Issei
authors.initials: I
authors.lastname: Komuro
mesh_terms: D000818:Animals; D006332:Cardiomegaly / Q000209:etiology; D006331:Heart Diseases / Q000209:etiology*; D017202:Myocardial Ischemia / Q000209:etiology; D047492:Peroxisome Proliferator-Activated Receptors / Q000502:physiology*
chemical_list: D047492:Peroxisome Proliferator-Activated Receptors